---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001964"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:19:33.310537+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Pelthos Therapeutics appoints Andrew Einhorn to Board of Directors; board expands to eight

## Summary
- Andrew Einhorn appointed to Board effective December 23, 2025, filling newly created eighth seat.
- Einhorn will serve on Audit and Compensation Committees; term until 2026 annual meeting.
- Einhorn brings 40+ years of finance, capital markets, and life sciences experience.
- Granted 12,000 RSUs vesting January 1, 2027, plus standard non-employee director compensation.
- Board expanded from seven to eight members; Einhorn deemed independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001753926-25-001964
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001964/0001753926-25-001964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001964/g085052_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001964
- JSON: https://secwatch.observer/filing/0001753926-25-001964.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.